Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
| Autor: | Gilad Itchaki, Inna Tzoran, Tsofia Inbar, Netanel A. Horowitz, Nurit Horesh, Eldad J. Dann, Moran Szwarcwort, Noa Lavi, Ronit Gurion, Mor Taylor-Abigadol, Chiya Leibovitch, Uri Rozovski, Anat Gafter-Gvili, Pia Raanani, Haim Ben-Zvi, Shimrit Ringelstein-Harlev, Riva Fineman |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
2019-20 coronavirus outbreak
COVID-19 Vaccines Lymphoma medicine.drug_class Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Monoclonal antibody Antibodies Viral Serology medicine Humans BNT162 Vaccine Vaccines biology business.industry SARS-CoV-2 Vaccination Antibody titer COVID-19 Hematology medicine.disease Positive response Cross-Sectional Studies Immunology biology.protein Antibody business |
| Zdroj: | Haematologica. 107(3) |
| ISSN: | 1592-8721 |
| Popis: | Patients with lymphoma, especially those treated with anti-CD20 monoclonal antibodies, suffer high COVID-19-associated morbidity and mortality. The goal of this study was to assess the ability of lymphoma patients to generate a sufficient humoral response after two injections of BNT162b2 Pfizer vaccine and to identify factors influencing the response. Antibody titers were measured with the SARS-CoV-2 IgG II Quant (Abbott ) assay in blood samples drawn from lymphoma patients 4 2 weeks after the second dose of vaccine. The cutoff for a positive response was set at 50 AU/mL. Positive serological responses were observed in 51% of the 162 patients enrolled in this cross-sectional study. In a multivariate analysis, an interval of 1 year after this therapy. The latter percentage was equal to that of patients never exposed to monoclonal antibodies. In conclusion, lymphoma patients, especially those recently treated with anti- CD20 monoclonal antibodies, fail to develop sufficient humoral response to BNT162b2 vaccine. While a serological response is not the only predictor of immunity, its low level could make this population more vulnerable to COVID-19, which implies the need for a different vaccination schedule for such patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|